MCID: HYP595
MIFTS: 69

Hypertension, Essential malady

Categories: Genetic diseases (common), Cardiovascular diseases, Blood diseases

Aliases & Classifications for Hypertension, Essential

About this section

Aliases & Descriptions for Hypertension, Essential:

Name: Hypertension, Essential 50 12 37
Essential Hypertension 11 13 68 25 48 66
Hypertension 50 33 25 2
Hypertension, Salt-Sensitive Essential, Susceptibility to 23
Susceptibility to Salt-Sensitive Essential Hypertension 23
Hypertension, Essential, Susceptibility to, 3 12
Hypertension, Essential, Susceptibility to, 4 12
Hypertension, Essential, Susceptibility to, 5 12
Hypertension, Essential, Susceptibility to, 6 12
Hypertension, Essential, Susceptibility to, 2 12
Hypertension, Essential, Susceptibility to, 1 12
Hypertension, Essential, Salt-Sensitive 50
 
Hypertension, Salt-Sensitive Essential 50
Hypertension, Essential 4 50
Hypertension, Essential 3 50
Hypertension, Essential 2 50
Hypertension, Essential 6 50
Hypertension, Essential 1 50
Hypertension, Essential 5 50
Idiopathic Hypertension 11
Primary Hypertension 11
Hypertensive Disease 66
Eht 68

Characteristics:

HPO:

62
hypertension, essential:
Inheritance: multifactorial inheritance


Classifications:



External Ids:

OMIM50 145500
Disease Ontology11 DOID:10825
ICD9CM30 401, 401.9
NCIt43 C3478
MedGen35 C0085580

Summaries for Hypertension, Essential

About this section
OMIM:50 The Pickering school held that blood pressure has a continuous distribution, that multiple genes and multiple... (145500) more...

MalaCards based summary: Hypertension, Essential, also known as essential hypertension, is related to malignant essential hypertension and benign essential hypertension, and has symptoms including chest pain, chest pain and cyanosis. An important gene associated with Hypertension, Essential is AGT (Angiotensinogen), and among its related pathways are NO-dependent CFTR activation (normal and CF) and Effects of nitric oxide. The drugs diltiazem and felodipine have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and endothelial, and related mouse phenotypes are adipose tissue and renal/urinary system.

Disease Ontology:11 A hypertension with no known cause. it is the most common type of hypertension.

CDC:2 About 1 of 3 U.S. adults—or about 70 million people—have high blood pressure.1Only about half (52%) of these people have their high blood pressure under control.1 This common condition increases the risk for heart disease and stroke, 2 of the leading causes of death for Americans.2Get more quick facts about high blood pressure, or learn more about high blood pressure in the United States.

UniProtKB/Swiss-Prot:68 Essential hypertension: A condition in which blood pressure is consistently higher than normal with no identifiable cause.

Wikipedia:69 Essential hypertension (also called primary hypertension or idiopathic hypertension) is the form of... more...

Related Diseases for Hypertension, Essential

About this section

Diseases in the Familial Hypertension family:

hypertension, essential Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Hypertension, Essential via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 72)
idRelated DiseaseScoreTop Affiliating Genes
1malignant essential hypertension12.3
2benign essential hypertension12.3
3hypertension, essential 712.1
4hypertension, essential 812.1
5pediatric ulcerative colitis11.2ACE, ADD1, AGT
6casr-related disorders11.1ACE, AGT, AGTR1, INS
7irritable bowel syndrome11.1ACE, AGT, AGTR1, NOS3
8antiphospholipid syndrome11.1ACE, AGT, AGTR1, REN
9chylocele of tunica vaginalis11.1ACE, AGT, AGTR1, REN
10fibula aplasia complex brachydactyly11.1ACE, AGT, AGTR1
11agammaglobulinemia 611.1ACE, AGT, AGTR1, INS
12hypodermyasis11.1ACE, CYP11B2, REN
13joint disorders11.1ACE, AGT, AGTR1, NOS3
14post-infectious myocarditis11.1ACE, AGT, AGTR1
15benign hypertensive renal disease11.1ACE, AGT, AGTR1, CYP11B2
16renal tubular dysgenesis11.1ACE, AGT, AGTR1, REN
17herpetic gastritis11.1ACE, AGT, AGTR1, NOS3
18podder-tolmie syndrome11.1ADD1, AGT, AGTR1
19ovarian cancer11.1ACE, AGT, AGTR1, NOS3, REN
20collecting duct carcinoma11.1ACE, AGT, AGTR1, CYP11B2, REN
21mononeuritis11.1ACE, AGT, AGTR1, INS, REN
22broad ligament malignant neoplasm11.1ACE, AGTR1, REN
23poikiloderma with neutropenia11.1AGTR1, ECE1, NOS2, NOS3
24hypoaldosteronism, congenital, due to cmo ii deficiency11.1AGT, CYP11B2, REN
25mental depression11.1ACE, NOS3, REN
26spinal canal and spinal cord meningioma11.1ACE, CYP11B2, NOS2, NOS3, REN
27aortic valves stenosis of the child11.1ACE, AGT, AGTR1, CYP11B2, GNB3, NOS3
28plica syndrome11.1ACE, AGT, REN
29craniosynostosis11.1ACE, AGTR1, INS, NOS3, REN
30diabetic encephalopathy11.1ACE, INS, NOS3, REN
31hypotelorism cleft palate hypospadias11.0ACE, REN
32littre gland carcinoma11.0ACE, AGT, AGTR1, INS, REN
33acute myeloblastic leukemia without maturation11.0ACE, AGTR1, NOS3
34periampullary adenoma11.0ACE, INS, NOS3, REN
35survival motor neuron spinal muscular atrophy11.0ACE, INS, NOS3, REN
36citrullinemia, adult-onset type ii11.0ACE, AGTR1, INS, NOS3
37gemistocytic astrocytoma11.0ACE, AGTR1, INS, NOS3, REN
38adenocarcinoma11.0ACE, AGTR1, REN
39peripheral artery disease11.0ACE, AGT, AGTR1, INS, NOS3, REN
40stroke, ischemic11.0ACE, AGTR1, NOS3, PTGIS, REN
41alpha-2-plasmin inhibitor deficiency11.0ACE, AGTR1, NOS3
42adrenal rest tumor11.0ACE, INS, NOS2, NOS3, REN
43neurilemmoma of the pleura11.0CYP11B2, INS, REN
44central nervous system angiosarcoma11.0ACE, INS, REN
45cystinosis11.0ACE, AGT, REN
46preeclampsia/eclampsia 111.0AGT, AGTR1, NOS3
47bubonic plague11.0AGTR1, NOS2, NOS3
48cystic kidney disease10.9ACE, REN
49hepatic adenoma, somatic10.9ACE, AGT, AGTR1, INS, NOS3, REN
50chronic myelomonocytic leukemia10.9ACE, INS, REN

Comorbidity relations with Hypertension, Essential via Phenotypic Disease Network (PDN):

(show top 50)    (show all 289)
Abducens Nerve DiseaseAcquired Polycythemia
Acute Closed-Angle GlaucomaAcute Conjunctivitis
Acute Stress DisorderAdjustment Disorder
Adrenal Hyperplasia, Congenital, Due to 21-Hydroxylase DeficiencyAlcohol Abuse
Anxiety DisorderAtypical Depressive Disorder
Auditory System DiseaseAutonomic Nervous System Disease
Benign Paroxysmal Positional NystagmusBipolar Disorder
BlepharitisBorderline Glaucoma
Borderline Personality DisorderBrain Cancer
Brain CompressionBrain Edema
Branch Retinal Artery OcclusionCalcium Metabolism Disease
CampylobacteriosisCentral Nervous System Origin Vertigo
Central Retinal Artery OcclusionCentral Retinal Vein Occlusion
Cerebral DegenerationChronic Closed-Angle Glaucoma
Common Peroneal Nerve LesionCommunicating Hydrocephalus
ConjunctivitisConversion Disorder
Corneal UlcerCortical Blindness
Cranial Nerve PalsyCushing's Syndrome
Deficiency AnemiaDependent Personality Disorder
DermatomycosisDermatophytosis
Developmental DyspraxiaDiabetes Mellitus, Noninsulin-Dependent
Diabetic KetoacidosisDiabetic Peripheral Angiopathy
Diabetic PolyneuropathyDysthymic Disorder
EncephalopathyEosinophilia
Facial ParalysisFemale Breast Cancer

Graphical network of the top 20 diseases related to Hypertension, Essential:



Diseases related to hypertension, essential

Symptoms for Hypertension, Essential

About this section

Symptoms by clinical synopsis from OMIM:

145500

Clinical features from OMIM:

145500

HPO human phenotypes related to Hypertension, Essential:

id Description Frequency HPO Source Accession
1 elevated systolic blood pressure HP:0004421
2 elevated mean arterial pressure HP:0004972
3 elevated diastolic blood pressure HP:0005117

UMLS symptoms related to Hypertension, Essential:


chest pain, cyanosis, diarrhea, exanthema, fatigue, lethargy, nausea, seizures, syncope, tremor, vomiting, malaise, cushingoid facies, feeling jittery, equilibration disorder

Drugs & Therapeutics for Hypertension, Essential

About this section

FDA approved drugs:

(show all 6)
id Drug Name Active Ingredient(s)16 Company Approval Date
1
Adcirca16 TADALAFIL Eli Lilly May 2009
FDA Label: Adcirca
Disease/s that Drug Treats:pulmonary arterial hypertension
Indications and Usage:16 ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II - III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). (1.1)
DrugBank Targets:14 cGMP-specific 3',5'-cyclic phosphodiesterase|Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A
Mechanism of Action:16 
Target: phosphodiesterase type 5 (PDE5)
Action: oral inhibitor
FDA: Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Pulmonary arterial hypertension is associated with impaired release of nitric oxide by the vascular endothelium and consequent reduction of cGMP concentrations in the pulmonary vascular smooth muscle. PDE5 is the predominant phosphodiesterase in the pulmonary vasculature. Inhibition of PDE5 by tadalafil increases the concentrations of cGMP resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed. Studies in vitro have demonstrated that tadalafil is a selective inhibitor of PDE5. PDE5 is found in pulmonary vascular smooth muscle, visceral smooth muscle, corpus cavernosum, skeletal muscle, platelets, kidney, lung, cerebellum, and pancreas.In vitro studies have shown that the effect of tadalafil is more potent on PDE5 than on other phosphodiesterases. These studies have shown that tadalafil is >10,000-fold more potent for PDE5 than for PDE1, PDE2, PDE4, and PDE7 enzymes, which are found in the heart, brain, blood vessels, liver, leukocytes, skeletal muscle, and other organs. Tadalafil is >10,000-fold more potent for PDE5 than for PDE3, an enzyme found in the heart and blood vessels. Additionally, tadalafil is 700-fold more potent for PDE5 than for PDE6, which is found in the retina and is responsible for phototransduction. Tadalafil is >9,000-fold more potent for PDE5 than for PDE8, PDE9, and PDE10. Tadalafil is 14-fold more potent for PDE5 than for PDE11A1 and 40-fold more potent for PDE5 than for PDE11A4, two of the four known forms of PDE11. PDE11 is an enzyme found in human prostate, testes, skeletal muscle and in other tissues. In vitro, tadalafil inhibits human recombinant PDE11A1 and, to a lesser degree, PDE11A4 activities at concentrations within the therapeutic range. The physiological role and clinical consequence of PDE11 inhibition in humans have not been defined.
2
Adempas16 RIOCIGUAT Bayer Healthcare Pharmaceuticals October 2013
FDA Label: Adempas
Disease/s that Drug Treats:Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
Indications and Usage:16 Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: * Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. (1.1) * Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. (1.2)
DrugBank Targets: -
Mechanism of Action:16 
Target: soluble guanylate cyclase (sGC)
Action: stimulator
FDA: Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation.Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding. Riociguat also directly stimulates sGC via a different binding site, independently of NO. Riociguat stimulates the NO-sGC-cGMP pathway and leads to increased generation of cGMP with subsequent vasodilation. The active metabolite (M1) of riociguat is 1/3 to 1/10 as potent as riociguat.
3
Covera-HS16 VERAPAMIL HYDROCHLORIDE GD Searle, Alza January 1996
FDA Label: Covera-HS
Disease/s that Drug Treats:hypertension, angina
Indications and Usage:16 COVERA-HS is indicated for the management of hypertension and angina.
DrugBank Targets:14 Voltage-dependent L-type calcium channel subunit alpha-1C|Voltage-dependent L-type calcium channel subunit alpha-1D|Voltage-dependent L-type calcium channel subunit alpha-1F|Voltage-dependent L-type calcium channel subunit alpha-1S|Voltage-dependent L-type calcium channel subunit beta-1|Voltage-dependent L-type calcium channel subunit beta-2|Voltage-dependent L-type calcium channel subunit beta-3|Voltage-dependent L-type calcium channel subunit beta-4|Voltage-dependent T-type calcium channel subunit alpha-1I|Voltage-dependent T-type calcium channel subunit alpha-1G|Voltage-dependent N-type calcium channel subunit alpha-1B|Voltage-dependent P/Q-type calcium channel subunit alpha-1A|Potassium voltage-gated channel subfamily H member 2|Sodium channel protein type 5 subunit alpha|ATP-sensitive inward rectifier potassium channel 11|Sodium-dependent serotonin transporter
Mechanism of Action:16 
Target: -
Action: -
FDA: In vitro: Verapamil binding is voltage-dependent with affinity increasing as the vascular smooth muscle membrane potential is reduced. In addition, verapamil binding is frequency dependent and apparent affinity increases with increased frequency of depolarizing stimulus. The L-type calcium channel is an oligomeric structure consisting of five putative subunits designated alpha-1, alpha-2, beta, tau, and epsilon. Biochemical evidence points to separate binding sites for 1,4-dihydropyridines, phenylalkylamines, and the benzothiazepines (all located on the alpha-1 subunit). Although they share a similar mechanism of action, calcium channel blockers represent three heterogeneous categories of drugs with differing vascular-cardiac selectivity ratios. Essential hypertension: Verapamil produces its antihypertensive effect by a combination of vascular and cardiac effects. It acts as a vasodilator with selectivity for the arterial portion of the peripheral vasculature. As a result, the systemic vascular resistance is reduced and usually without orthostatic hypotension or reflex tachycardia. Bradycardia (rate less than 50 beats/min) is uncommon (<1% with COVERA-HS as assessed by ECG). During isometric or dynamic exercise, COVERA-HS does not alter systolic cardiac function in patients with normal ventricular function. COVERA-HS does not alter total serum calcium levels. However, one report has suggested that calcium levels above the normal range may alter the therapeutic effect of verapamil. COVERA-HS regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles. Effects in hypertension: COVERA-HS was evaluated in two placebo-controlled, parallel design, double-blind studies of 382 patients with mild to moderate hypertension. In a clinical trial, 287 patients were randomized to placebo, 120 mg, 180 mg, 360 mg, or 540 mg and treated for 8 weeks (the two higher doses were titrated from low doses and maintained for 6 and 4 weeks, respectively). COVERA-HS or placebo was given once daily at 10 pm and blood pressure changes were measured with 36-hour ambulatory blood pressure monitoring (ABPM). The results of these studies demonstrate that COVERA-HS, at 180-540 mg, is a consistently and significantly more effective antihypertensive agent than placebo in reducing ambulatory blood pressures. Over this dose range, the placebo-subtracted net decreases in diastolic BP at trough (averaged over 6-10 pm) were dose-related, ranged from 4.5 to 11.2 mm Hg after 4-8 weeks of therapy, and correlated well with sitting cuff blood pressures. These studies demonstrate that clinically and statistically significant blood pressure reductions are achieved with COVERA-HS throughout the 24-hour dosing period. There were no significant treatment differences between patient subgroups of different age (older or younger than 65 years), sex, race (Caucasian and non-Caucasian) and severity of hypertension at baseline (cuff BP below and above 105 mm Hg). Angina: Verapamil dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with coronary artery spasm and is responsible for the effectiveness of verapamil in vasospastic (Prinzmetal’s or variant) as well as unstable angina at rest. Whether this effect plays any role in classical effort angina is not clear, but studies of exercise tolerance have not shown an increase in the maximum exercise rate-pressure product, a widely accepted measure of oxygen utilization. This suggests that, in general, relief of spasm or dilation of coronary arteries is not an important factor in classical angina. Verapamil regularly reduces the total systemic resistance (afterload) against which the heart works both at rest and at a given level of exercise by dilating peripheral arterioles. Effect in chronic stable angina: COVERA-HS was evaluated in two placebocontrolled, parallel design, double-blind studies of 453 patients with chronic stable angina. In the first clinical trial, 277 patients were randomized to placebo, 180 mg, 360 mg, or 540 mg and treated for 4 weeks (the two higher doses were titrated from low doses and maintained for 3 and 2 weeks, respectively). A single dose of 240 mg was compared toplacebo in a separate study of 176 patients. In these studies, COVERA-HS was significantly more effective than placebo in improvement of exercise tolerance. Placeboadjusted net increases in median exercise times at the end of the dosing interval were 0.1 to 1.0 minute for symptom limited duration, 0.3 to 1.4 minutes for time to angina, and 0.1 to 1.1 minutes for time to ST change. Increases in exercise tolerance were in general greater at higher doses, but dose-response relationship was not well defined due to shorter treatment duration for high doses. In addition, in the first study, 24% to 34% of patients treated with COVERA-HS did not experience exercise-limiting angina on exercise treadmill testing (ETT) versus 12% of patients on placebo. Electrophysiologic effects: Electrical activity through the AV node depends, to a significant degree, upon the transmembrane influx of extracellular calcium through the Ltype (slow) channel. By decreasing the influx of calcium, verapamil prolongs the effective refractory period within the AV node and slows AV conduction in a rate-related manner. Normal sinus rhythm is usually not affected, but in patients with sick sinus syndrome, verapamil may interfere with sinus-node impulse generation and may induce sinus arrest or sinoatrial block. Atrioventricular block can occur in patients without preexisting conduction defects (see WARNINGS). COVERA-HS does not alter the normal atrial action potential or intraventricular conduction time, but depresses amplitude, velocity of depolarization, and conduction in depressed atrial fibers. Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract. Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil (see WARNINGS). Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis. It is not known whether this action is important at the doses used in man.
4
Letairis16 AMBRISENTAN Gilead June 2007
FDA Label: Letairis
Disease/s that Drug Treats:pulmonary arterial hypertension
Indications and Usage:16 Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): * To improve exercise ability and delay clinical worsening. * In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II-III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) (1).
DrugBank Targets:14 Endothelin-1 receptor|Endothelin B receptor
Mechanism of Action:16 
Target: endothelin receptor
Action: type-A selective antagonist
FDA: Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and cell proliferation, while the predominant actions of ETB are vasodilation, antiproliferation, and ET-1 clearance. In patients with PAH, plasma ET-1 concentrations are increased as much as 10-fold and correlate with increased mean right atrial pressure and disease severity. ET-1 and ET-1 mRNA concentrations are increased as much as 9-fold in the lung tissue of patients with PAH, primarily in the endothelium of pulmonary arteries. These findings suggest that ET-1 may play a critical role in the pathogenesis and progression of PAH. Ambrisentan is a high-affinity (Ki=0.011 nM) ETA receptor antagonist with a high selectivity for the ETA versus ETB receptor (>4000-fold). The clinical impact of high selectivity for ETA is not known.
5
Opsumit16 MACITENTAN Actelion Pharmaceuticals October 2013
FDA Label: Opsumit
Disease/s that Drug Treats:pulmonary arterial hypertension
Indications and Usage:16 OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). OPSUMIT also reduced hospitalization for PAH (1.1).
DrugBank Targets:14 Endothelin-1 receptor|Endothelin B receptor
Mechanism of Action:16 
Target: Endothelin Receptor
Action: antagonist
FDA: Endothelin (ET)-1 and its receptors (ETA and ETB) mediate a variety of deleterious effects, such as vasoconstriction, fibrosis, proliferation, hypertrophy, and inflammation. In disease conditions such as PAH, the local ET system is upregulated and is involved in vascular hypertrophy and in organ damage. Macitentan is an endothelin receptor antagonist that prevents the binding of ET-1 to both ETA and ETB receptors. Macitentan displays high affinity and sustained occupancy of the ET receptors in human pulmonary arterial smooth muscle cells. One of the metabolites of macitentan is also pharmacologically active at the ET receptors and is estimated to be about 20% as potent as the parent drug in vitro.
6
Remodulin16 TREPROSTINIL United Therapeutics May 2002
FDA Label: Remodulin
Disease/s that Drug Treats:pulmonary arterial hypertension
Indications and Usage:16 Remodulin is a prostacyclin vasodilator indicated for: * Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%) (1.1) * Patients who require transition from Flolan®, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. (1.2)
DrugBank Targets:14 Prostacyclin receptor|Peroxisome proliferator-activated receptor delta|P2Y purinoceptor 12
Mechanism of Action:16 
Target: pulmonary and systemic arterial vascular beds|platelet aggregation
Action: direct vasodilation|inhibition
FDA: The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.

Drugs for Hypertension, Essential (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 534)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Uric acidPhase 4, Phase 3, Phase 2, Phase 112769-93-21175
Synonyms:
1H-Purine-2,6,8-triol
2,6,8-Trihydroxypurine
2,6,8-Trioxopurine
2,6,8-Trioxypurine
 
7,9-dihydro-1H-purine-2,6,8(3H)-trione
Lithate
Lithic acid
Purine-2,6,8(1H,3H,9H)-trione
Urate
Uric acid
2
FebuxostatPhase 4, Phase 251144060-53-7134018
Synonyms:
111GE013
144060-53-7
2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID
2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid
2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid
2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid
2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
AC-425
AC1L33UC
Adenuric
C16H16N2O3S
CHEBI:45943
CHEBI:747206
CHEMBL1164729
CID134018
D01206
DB03786
 
FT-0081351
Febuxostat
Febuxostat (JAN/USAN/INN)
Febuxostat [USAN]
Febuxostatum
Fébuxostat
LS-173202
MolPort-005-940-740
S1547
S1547_Selleck
TEI
TMX 67
TMX-67
TMX-67, Adenuric, Uloric, Febuxostat
Tei 6720
Tei-6720
UNII-101V0R1N2E
Uloric
3Epoetin alfaPhase 4, Phase 2, Phase 1638113427-24-0
4
SimvastatinPhase 4, Phase 3, Phase 1, Phase 250379902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
5
NicardipinePhase 4, Phase 3, Phase 2, Phase 12955985-32-54474
Synonyms:
2-(Benzylmethylamino)ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)pyridine-3,5-dicarboxylate
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-(benzylmethylamino)ethyl methyl ester
5-O-[2-[benzyl(methyl)amino]ethyl] 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
55985-32-5
AB00514658
AC-19947
AC1L1I8Y
AKOS001637090
Ambap55985-32-5
BIDD:GT0621
BPBio1_000623
BRD-A26711594-001-02-7
BRD-A26711594-003-05-6
BRN 0504321
BSPBio_000565
BSPBio_001389
BSPBio_002943
Bio1_000088
Bio1_000577
Bio1_001066
Bio2_000109
Bio2_000589
C07264
C26H29N3O6
CBiol_001802
CHEBI:507549
CHEMBL1484
CID4474
Cardene
Cardene (TN)
Cardene IV
D08270
DB00622
DivK1c_000540
EINECS 259-932-3
HMS1791F11
HMS1989F11
HMS2089C09
IDI1_000540
IDI1_033859
KBio1_000540
 
KBio2_000109
KBio2_001852
KBio2_002677
KBio2_004420
KBio2_005245
KBio2_006988
KBio3_000217
KBio3_000218
KBio3_002443
KBioGR_000109
KBioGR_000744
KBioSS_000109
KBioSS_001852
L000715
LS-131263
Lopac0_000809
MolPort-002-484-049
NCGC00015747-06
NCGC00162262-01
NCGC00162262-02
NCGC00162262-03
NCGC00162262-04
NINDS_000540
Nicardipine (INN)
Nicardipine LA
Nicardipine [INN:BAN]
Nicardipino
Nicardipino [INN-Spanish]
Nicardipinum
Nicardipinum [INN-Latin]
Oprea1_436998
Prestwick0_000383
Prestwick1_000383
Prestwick2_000383
Prestwick3_000383
SPBio_001490
SPBio_002486
Spectrum2_001415
Spectrum3_001452
Spectrum4_000422
Spectrum5_001320
Spectrum_001372
UNII-CZ5312222S
Y-93
methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
nicardipine
6
TerlipressinPhase 4, Phase 24814636-12-572081
Synonyms:
(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide
(2s)-1-{[(4r,7s,10s,13s,16s,19r)-19-{[({[(aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-n-{(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl}pyrrolidine-2-carboxamide(non-preferred name)
14636-12-5
AC1L2HDP
AC1Q5JB2
CID72081
DB02638
EINECS 238-680-8
HS-2028
LS-161411
 
Lucassin
N-(N-(N-Glycylglycyl)glycyl)-8-L-lysinevasopressin
Terlipressin
Terlipressin [BAN:INN]
Terlipressina
Terlipressina [INN-Spanish]
Terlipressine
Terlipressine [INN-French]
Terlipressinum
Terlipressinum [INN-Latin]
UNII-7Z5X49W53P
glypressin
7
PrazosinPhase 4, Phase 1, Phase 25919216-56-94893
Synonyms:
1-(3-Amino-6,7-dimethoxy-2- quinazolinyl)-4-(2-furanyl-carbonyl)piperazine hydrochloride
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) piperazine
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
19216-56-9
2-(4-(2-Furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
4-(4-Amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone
5-25-13-00365 (Beilstein Handbook Reference)
AB00053528
AC1L1J6T
AKOS000310009
BCBcMAP01_000227
BPBio1_001006
BRD-K49111258-001-02-8
BRD-K49111258-003-05-7
BRN 0768345
BSPBio_000914
BSPBio_001036
BSPBio_002221
Bio1_000365
Bio1_000854
Bio1_001343
Bio2_000358
Bio2_000838
C07368
C19H21N5O4
CAS-19237-84-4
CHEBI:8364
CHEMBL2
CID4893
CP-12299
D08411
DB00457
DivK1c_000375
EINECS 242-885-8
Furazosin
HMS1362D17
HMS1792D17
HMS1990D17
HMS2089G09
HSDB 3298
IDI1_000375
IDI1_002113
Justac
KBio1_000375
KBio2_000376
KBio2_001302
KBio2_002944
KBio2_003870
KBio2_005512
KBio2_006438
KBio3_000731
KBio3_000732
KBio3_001721
KBioGR_000376
KBioGR_000965
KBioSS_000376
KBioSS_001302
 
L000666
LS-140002
Lentopres
Minipress
Minipress (TN)
Minipress Xl
MolPort-000-891-036
NCGC00016740-01
NCGC00016740-02
NCGC00016740-03
NCGC00016740-14
NCGC00024324-02
NCGC00024324-04
NCGC00024324-05
NCGC00024324-06
NCGC00024324-07
NCGC00024324-08
NCGC00024324-09
NCI60_002417
NINDS_000375
Oprea1_314778
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)- (9CI)
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)- (8CI)
Prazocin
Prazosin (INN)
Prazosin HCl
Prazosin Hydrochloride
Prazosin [INN:BAN]
Prazosina
Prazosina [INN-Spanish]
Prazosine
Prazosine [INN-French]
Prazosinum
Prazosinum [INN-Latin]
Prestwick0_000947
Prestwick1_000947
Prestwick2_000947
Prestwick3_000947
SMP1_000063
SPBio_001297
SPBio_003073
ST075549
STK301545
Spectrum2_001289
Spectrum3_000551
Spectrum4_000483
Spectrum5_001365
Spectrum_000822
TL8001573
TNP00312
Tocris-0623
UNII-XM03YJ541D
Vasoflex
ZINC00601304
[3H]-Prazosin
[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-(2-furyl)methanone
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](furan-2-yl)methanone
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone
prazosin
8
EplerenonePhase 4, Phase 3, Phase 2, Phase 192107724-20-9150310, 443872
Synonyms:
107724-20-9
7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone
AC-4213
AC1L9FDC
C12512
CGP-30083
CHEBI:31547
CHEBI:726453
CHEMBL1095097
CID443872
D01115
Eplerenone
 
Eplerenone (JAN/USAN/INN)
Epoxymexrenone
Inspra
Inspra (TN)
Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone
MolPort-003-986-216
NCGC00159559-01
NCGC00159559-02
S1707_Selleck
SC-66110
Selara
TL8000270
ZINC03985982
9
Isosorbide DinitratePhase 4, Phase 3, Phase 2, Phase 15887-33-26883
Synonyms:
1,4:3, 6-Dianhydro-D-glucitol dinitrate
1,4:3,6-Dianhydro-D-glucitol dinitrate
1,4:3,6-Dianhydrosorbitol 2, 5-dinitrate
1,4:3,6-Dianhydrosorbitol 2,5-dinitrate
1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol
54650-95-2
59812_ALDRICH
59812_FLUKA
6659-58-1
87-33-2
AB00513900
AC-12153
AC1L1NIG
Angidil
Astridine
BPBio1_001021
BSPBio_000927
BSPBio_002080
BiDil
C07456
C6H8N2O8
CCRIS 1910
CHEBI:6061
CID6883
Cardio 10
Cardis
Cardonit 40
Carvanil
Carvasin
Cedocard
Cedocard Retard
Cedocard retard
Claodical
Cornilat
Coronex
Corosorbide
Corovliss
D-Glucitol, 1,4:3,6-dianhydro-, 2,5-dinitrate
D-Glucitol, 1,4:3,6-dianhydro-, dinitrate
D-Isosorbide dinitrate
D-Isosorbide dinitrate-Lactose mixture
D00516
D007548
DB00883
Dianhydrosorbitol 2,5-dinitrate
Difutrat
Dignionitrat
Dilatrate
Dilatrate SR
Dilatrate-SR
Dilatrate-sr (TN)
Diniket
Dinitrate d'isosorbide
Dinitrate d'isosorbide [INN-French]
Dinitrate, Isosorbide
Dinitrato de isosorbida
Dinitrato de isosorbida [INN-Spanish]
Dinitroisosorbide
Dinitrosorbide
Disorlon
DivK1c_000436
EINECS 201-740-9
Emoper
EureCor
Flindix
Frandol
Glucitol, 1,4:3, 6-dianhydro-, dinitrate,
HMS1570O09
HMS1920H15
HMS2091P05
HMS501F18
HSDB 3417
Harrical
IBD 20
IDI1_000436
ISD
ISDN
ISOSORBIDE DINITRATE
Ismotic
Iso Bid
Iso-Bid
Iso-Mack
Iso-Puren
IsoBid
Isochron
Isodinit
Isoket
Isoket Retard 120
Isoket Retard-120
Isoket Retard120
 
Isoket retard 40
Isomak R
Isorbid
Isordil
Isordil (TN)
Isordil Tembids
Isosorbide 2,5-dinitrate
Isosorbide dinitrate
Isosorbide dinitrate (JP15/USP/INN)
Isosorbide dinitrate [USAN:INN:BAN:JAN]
Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907] [Flammable solid]
Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907] [Flammable solid]
Isosorbide dinitrato
Isosorbide dinitrato [DCIT]
Isosorbidi dinitras
Isosorbidi dinitras [INN-Latin]
Isosorbidi nitras
Isostat
Isotrate
KBio1_000436
KBio2_000643
KBio2_003211
KBio2_005779
KBio3_001580
KBioGR_000429
KBioSS_000643
Korodil
LS-71376
Langoran
Laserdil
Lomilan
MLS001333561
MLS001333562
Maycor
MolPort-003-666-213
Myorexon
NCGC00178830-01
NCGC00178830-02
NINDS_000436
NSC 80038
NSC80038
Nitrosorbid
Nitrosorbide
Nitrosorbon
Nosim
Prestwick0_000714
Prestwick1_000714
Prestwick2_000714
Prestwick3_000714
Prestwick_81
Resoidan
Rifloc Retard
Rigedal
SDM No. 40
SDM No. 50
SMR000857256
SPBio_001058
SPBio_002848
SPECTRUM1500358
SST-101
Sorate-10
Sorate-5
Sorbangil
Sorbide
Sorbide T.D.
Sorbide nitrate
Sorbide, dinitrate
Sorbidi nitras
Sorbidilat
Sorbidinitrate
Sorbidnitrate
Sorbislo
Sorbitrate
Sorbonit
Sorquad
Sorquat
Spectrum2_001069
Spectrum3_000600
Spectrum4_000025
Spectrum5_001057
Spectrum_000163
TYB 3215
Tinidil
Titradose
UN2907
UNII-IA7306519N
Vascardin
Vasodilat
Vasorbate
Xanyl
ZINC18089317
[(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
10isosorbide-5-mononitratePhase 4, Phase 3, Phase 2, Phase 158
11
NadololPhase 4, Phase 3, Phase 12142200-33-939147
Synonyms:
(2R,3S)-5-(3-(tert-Butylamino)-2-hydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol
(2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
2,3-cis-1,2,3,4-Tetrahydro-5-((2-hydroxy-3-tert-butylamino)propoxy)-2,3-naphthalenediol
42200-33-9
5-(3-((1,1-Dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediol
AC1L2151
AC1Q1MO3
AC1Q77IZ
Anabet
BRD-A87606379-001-03-4
BSPBio_003152
CCRIS 1048
CHEMBL649
CID39147
CPD000058975
Corgard
Corgard (TN)
Corgaretic
D00432
D009248
DB01203
DivK1c_000427
EINECS 255-706-3
HMS1570D17
HMS1922O05
HMS2093A15
HMS501F09
HSDB 6532
IDI1_000427
KBio1_000427
KBio2_002123
KBio2_004691
KBio2_007259
 
KBio3_002652
KBioGR_000765
KBioSS_002123
LS-94578
MLS000028580
MLS001148087
MolPort-003-666-474
NCGC00089811-02
NINDS_000427
Nadic
Nadolol (JP15/USP/INN)
Nadolol [USAN:BAN:INN:JAN]
Nadololum
Nadololum [INN-Latin]
Prestwick0_000818
Prestwick1_000818
Prestwick2_000818
Prestwick_108
SAM002264627
SMP1_000203
SMR000058975
SPBio_001392
SPBio_002636
SPECTRUM1503260
SQ 11725
SQ-11725
SQ11725
Solgol
Spectrum2_001546
Spectrum3_001586
Spectrum4_000193
Spectrum5_001255
Spectrum_001643
UNII-FEN504330V
VU0239635-6
nadolol
12
AspirinPhase 4, Phase 2, Phase 3, Phase 1107450-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(ACETYLOXY)benzoic acid
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide 2-(acetyloxy)benzoique
Acide acetylsalicylique
Acide acétylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
 
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
ácido acetilsalicílico
13
ClopidogrelPhase 4, Phase 3, Phase 2733120202-66-6, 113665-84-260606
Synonyms:
( )-(S)-Clopidogrel
(+)-(S)-Clopidogrel
(+)-Clopidogrel
(S)-Clopidogrel
(S)-Methyl 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate
113665-84-2
AC-19024
AC1L1TKZ
AC1Q41I9
BIDD:GT0284
BRD-K27721098-065-02-9
BSPBio_003211
C16H16ClNO2S
CGE
CHEBI:37941
CHEMBL1771
CID60606
CLOPIDOGREL SULFATE
CPD000550475
Clopidogrel
Clopidogrel (INN)
Clopidogrel (TN)
Clopidogrel [BAN:INN]
Clopidogrel [Ban:Inn]
Clopidogrel [INN:BAN]
Clopidogrel bisulfate
Clopidogrel bisulphate
Clopidogrel sulfate
Clopidogrelum
D07729
DB00758
DivK1c_000787
HMS2090O21
HMS502H09
HSDB 7430
IDI1_000787
 
Isocover
KBio1_000787
KBio2_000545
KBio2_003113
KBio2_005681
KBio3_002431
KBioGR_000689
KBioSS_000545
LS-172232
MLS001165708
MLS001195633
MLS001304711
Methyl (+)-(S)-alpha-(o-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4H)-acetate
MolPort-002-885-817
MolPort-003-845-991
NCGC00163329-02
NINDS_000787
Plavix
Plavix (TN)
SAM002589956
SMR000550475
SPBio_000463
SR 25990
STK580572
STOCK5S-27782
Spectrum2_000512
Spectrum3_001606
Spectrum4_000175
Spectrum_000105
TL8000400
UNII-A74586SNO7
Zyllt
clopidogrel
clopidogrel, (+)(S)-isomer
methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate
methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate
nchem.651-comp8
14
MannitolPhase 4, Phase 2, Phase 325769-65-8453, 6251
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
AR-1J3861
Ambap69-65-8
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-Mannitol
D-Mannitol (JP15)
D-mannite
D-mannitol
D00062
D008353
DL-Mannitol
Diosmol
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
HSDB 714
Hexahydroxyhexane
Hexanhexol
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
M9546_SIAL
M9647_SIAL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
 
MANNITOL 25%
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
MLS001335977
MLS001335978
MTL
Manicol
Manitol
Maniton S
Maniton-S
Manna Sugar
Manna sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol 10%
Mannitol 10% In Plastic Container
Mannitol 15%
Mannitol 15% In Plastic Container
Mannitol 20%
Mannitol 20% In Plastic Container
Mannitol 5%
Mannitol 5% In Plastic Container
Mannitol [USAN]
Mannitolum
Mannogem 2080
Marine Crystal
Marine crystal
MolPort-003-927-039
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
Osmitrol 15% In Water
Osmitrol 20% In Water
Osmitrol 5% In Water
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Sorbitol-Mannitol
TL806434
UNII-3OWL53L36A
ZINC02041302
bmse000099
cpd without stereochemical designation
e 421
e-421
e421
manita
mannitol
15
TobramycinPhase 411632986-56-45496, 36294
Synonyms:
1-Epitobramycin
11098-01-4
11111-45-8
3'-Deoxykanamycin B
3'-Deoxykanamycin b
32986-56-4
34337-51-4
37321-13-4
49842-07-1 (Sulfate)
54330-95-9
70322-33-7
79645-27-5
A 12253A
AB00513858
AC1L1KGY
AC1L1VI0
AC1O7GFJ
AC1Q2AOW
AKOS000715235
Aktob
BAS 00463364
BIDD:GT0503
BPBio1_000647
BRN 1357507
BSPBio_000587
BSPBio_002036
Brulamycin
C00397
C18H37N5O9
CAS-32986-56-4
CHEBI:28864
CHEBI:533587
CHEMBL1747
CID11340303
CID36294
CID5496
CID6604388
CID9804613
CID9934285
CPD000058793
D00063
DB00684
Deoxykanamycin B
Distobram
EINECS 251-322-5
Gotabiotic
HMS1569N09
HMS2090B16
HMS2092M17
HSDB 3259
KBio2_001552
KBio2_004120
KBio2_006688
KBio3_001536
KBioGR_001104
KBioSS_001552
LS-146940
LS-187329
Lilly 47663
MLS000069544
MolPort-001-934-131
MolPort-003-665-548
MolPort-003-939-629
NCGC00016814-01
NCGC00178852-01
NCGC00178852-02
NEBRAMYCIN
NF 6
NSC 180514
 
NSC180514
Nebcin
Nebcin (Sulfate)
Nebicin
Nebramycin 6
Nebramycin VI
Nebramycin factir 6
Nebramycin factor 6
Nebramycin-Faktor 6
O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Obracin
Obramycin
Prestwick0_000544
Prestwick1_000544
Prestwick2_000544
Prestwick3_000544
Prestwick_850
S2514_Selleck
SAM001246911
SMR000058793
SPBio_000295
SPBio_002508
SPECTRUM1500579
SPRC-AB01
STK182610
Spectrum2_000078
Spectrum3_000588
Spectrum4_000752
Spectrum5_001038
Spectrum_001072
Sybryx
T4014_SIGMA
TOA-(1-6)2TB-(4-1)TOC
TOA-(1-6)TOB-(4-1)TOC
TOBRAMYCIN SULFATE
TOY
Tenebrimycin
Tenemycin
Tobacin
Tobi
Tobracin
Tobracin (TN)
Tobracin (tn)
Tobradex
Tobradistin
Tobralex
Tobramaxin
Tobramicin
Tobramicina
Tobramicina [INN-Spanish]
Tobramitsetin
Tobramycetin
Tobramycin
Tobramycin (JP15/USP)
Tobramycin Sulfate
Tobramycin [USAN:BAN:INN:JAN]
Tobramycin for Inhalation
Tobramycin solution for inhalation
Tobramycin, Free Base
Tobramycine
Tobramycine [INN-French]
Tobramycinum
Tobramycinum [INN-Latin]
Tobrased
Tobrasone
Tobrex
Tobrex (TN)
Tobrex (tn)
UNII-VZ8RRZ51VK
tobramycin
tobramycin solution for inhalation
16
Mycophenolate mofetilPhase 4, Phase 3, Phase 2, Phase 1919128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
17
Mycophenolic acidPhase 4, Phase 3, Phase 2, Phase 191924280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
18
TacrolimusPhase 4, Phase 3, Phase 21058104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
19
LoteprednolPhase 44982034-46-6, 129260-79-3444025, 9865442
Synonyms:
82034-46-6
AC1L9FKJ
AKOS005145741
Alrex
Alrex, Lotemax, Loteprednol etabonate
CDDD-5604
CHEBI:31784
CHEMBL1200865
CID444025
CPD000469178
D01689
DB00873
HGP-1
HMS2051F16
IDR-90102
IDR-90103
Locort
 
Loteflam
Lotemax
Lotemax (TN)
Loteprednol
Loteprednol Etabonate
Loteprednol etabonate
Loteprednol etabonate (JAN/USAN)
Loteprednolum
Loterox
MLS001424221
MolPort-003-848-424
NCGC00164594-01
P-5604
S1669_Selleck
SAM001246630
SMR000469178
ZINC03920673
chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
chloromethyl 17alpha-[(ethoxycarbonyl)oxy]-11beta-hydroxy-3-oxoandrosta-1,4-diene-17beta-carboxylate
20glucocorticoidsPhase 4, Phase 24756
21
DexmedetomidinePhase 4, Phase 2, Phase 351576631-46-4, 113775-47-668602, 5311068, 56032
Synonyms:
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
113775-47-6
4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
DEXMEDETOMIDINE
 
Dexdor (T)
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
Dexmedetomidine (USAN/INN)
Dexmedetomidinum
Dexmédétomidine
MPV 1440
MPV-1440
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
NCGC00025347-01
PRECEDEX
Precedex (TN)
Tocris-2023
ZINC04632106
22
OctreotidePhase 4, Phase 1, Phase 220683150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
23
DexamethasonePhase 4200150-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
24Dexamethasone acetatePhase 420011177-87-3
25
PaclitaxelPhase 4269133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
26
EsmololPhase 4, Phase 3, Phase 152103598-03-4, 81147-92-459768
Synonyms:
(+-)-Esmolol
(+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
(±)-esmolol
(±)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
103598-03-4
3-[4-(2-Hydroxy-3-isopropylamino-propoxy)-phenyl]-propionic acid methyl ester
81147-92-4
81161-17-3 (Hydrochloride)
84057-94-3
AC-12058
AC1L1RWQ
AC1Q5ZXA
ASL 8052-001
BRN 5287174
Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester
C06980
CHEBI:4856
 
CHEMBL768
CID59768
D07916
DB00187
ESMOLOL
Esmolol (INN)
Esmolol [INN:BAN]
HMS2090P06
L001332
LS-185019
LS-31121
Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate
MolPort-005-933-593
UNII-MDY902UXSR
methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate
methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate
methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate
methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate
methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate
27
sirolimusPhase 4, Phase 3, Phase 2, Phase 1186353123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
28
PravastatinPhase 4, Phase 314781093-37-054687
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-1-Naphthaleneheptanoic acid
3beta-Hydroxycompactin
81093-37-0
81131-70-6 (hydrochloride salt)
AC1L1HJL
AC1Q5T3M
BIDD:GT0773
BRD-K60511616-236-01-4
C01844
C23H36O7
CCRIS 7557
CHEMBL1144
CID54687
Compactin
D08410
DB00175
Elisor
Eptastatin
FT-0082682
KS-5015
LS-94713
Lipostat
Mevalothin
Mevalotin
Mevastatin
Mevinolin
 
Oliprevin
Pravachol
Pravaselect
Pravastatin (INN)
Pravastatin Sodium
Pravastatin Sodium Salt
Pravastatin [INN:BAN]
Pravastatin acid
Pravastatin sodium
Pravastatin tert-Octylamine Salt
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
Pravator (TN)
RMS-431
SQ-31,000
Selectin
Selektine
Selipran
UNII-KXO2KT9N0G
Vasten
nchembio.301-comp7
nchembio790-comp15
pravastatin
pravastatina
pravastatine
pravastatinum
29
FluticasonePhase 461590566-53-3, 80474-14-262924, 22833648
Synonyms:
90566-53-3
AC-456
AC1NSJZT
Asmatil
Axotide
BIDD:GT0819
Brethal
C07815
CHEMBL1201396
CID5311101
Cultivate
Cutivate
D07981
Flixonase
Flixonase Nasal Spray
Flixotide
Flixotide Disk
 
Flixotide Disks
Flixotide Inhaler
Flonase
Flovent
Flovent Diskus
Flovent Rotadisk
Fluinol
Flunase
Flusonal
Fluspiral
Fluticaps
Fluticaps (TN)
Fluticasone (INN)
Fluticasonpropionat Allen
Flutide
Flutivate
MolPort-006-666-449
S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate
fluticasone
30
PerindoprilPhase 4, Phase 3, Phase 246107133-36-8, 82834-16-0107807
Synonyms:
(2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid
(2S,3AS,7as)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid
(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid
82834-16-0
82834-16-0 (Parent)
99149-83-4
AC1L32S9
ACEON
Aceon
BIDD:GT0786
BRD-K92731339-227-02-3
BSPBio_003206
C07706
C19H32N2O5
CHEBI:8024
CHEMBL1581
CID107807
Coverene Cor
Coverex
Coversum
Coversyl
D03753
DB00790
DW-7950
 
KBio2_002494
KBio2_005062
KBio2_007630
KBio3_002426
KBioGR_001190
KBioSS_002502
LS-178402
MLS002154153
McN-A-2833
MolPort-005-935-307
PERINDOPRIL
Perindopril (USAN/INN)
Perindopril Erbumine
Perindoprilum
Prestarium
S-9490
SED-9490
SMR001233453
SPBio_001216
Spectrum2_001108
Spectrum3_001683
Spectrum4_000775
Spectrum5_001689
Spectrum_001948
cpd with unspecified MF
ethyl N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvalinate
31
MentholPhase 4, Phase 2, Phase 3, Phase 121842216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
32
PitavastatinPhase 4, Phase 3, Phase 163147511-69-1, 147526-32-76366718, 5282452
Synonyms:
( )-(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid
(3R,5S,6E)-7-(2-Cyclopropyl-4-(p-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoic acid
(3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoate
(E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid
111GE002
147511-69-1
147526-32-7
2C25H23FNO4.Ca
AC1NR03G
AC1NR03J
AKOS005145916
Alipza
Bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt
C13334
CCRIS 8652
CID5282451
CID5282452
D01862
Itavastatin
Itavastatin calcium
KS-1220
LS-190698
 
LS-74594
LS-74595
Livalo
Livalo (TN)
Livalo, Pitavastatin calcium
Livazo
MolPort-006-822-984
NK 104
NK-104
NKS-104
Nisvastatin
P 872441
P-872441
Pitavastatia
Pitavastatin
Pitavastatin [INN]
Pitavastatin calcium
Pitavastatin calcium (JAN)
Pitavastatin hemicalcium
Pitavastatine
Pitavastatinum
S1759_Selleck
ZINC01534965
calcium (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate
33
EverolimusPhase 4, Phase 3, Phase 2, Phase 11863159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
34cloprostenolPhase 4, Phase 313
35
imidaclopridPhase 4154105827-78-986418
Synonyms:
(e)-imidacloprid
(z)-imidacloprid
1-((6-Chloro-3-pyridyl)methyl)-N-nitro-2-imidazolidinimine
1-(2-Chloro-5-pyridylmethyl)-2-(nitroimino)imidazolidine
1-[(6-Chloro-3-pyridinyl)methyl]-4,5-dihydro-N-nitro-1H-imidazol-2-amine, 9CI
Admire
Advantage
Advantage flea adulticide
Bayer brand of imidacloprid
 
Confidor
Confidor 200 SL
Confidor SL
Gaucho
Imidacloprid (old RN)
Imidacloprid [iso]
Merit
Merit (insecticide)
Premise 75
Provado
36
CelecoxibPhase 4, Phase 3, Phase 1, Phase 2427169590-42-52662
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC-4228
AC1L1E6K
AI-525
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
CPD000550473
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
Celecoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
Célécoxib
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
KBio2_000912
 
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
MLS001165684
MLS001195656
MLS001304708
Medicoxib
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC-58635
SC58635
SMR000550473
SPBio_001512
SPECTRUM1503678
Solexa
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
Spectrum_000432
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM-177
YM177
ZINC02570895
cMAP_000027
celecoxib
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
37BenidipinePhase 42105979-17-7
38
TrichlormethiazidePhase 4, Phase 32133-67-55560
Synonyms:
(+-)-6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
133-67-5
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-, 1,1-dioxide
2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(dichloromethyl)-3,4-dihydro-,1,1-dioxide
3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
3-(Dichloromethyl)-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide
3-Dichloromethyl-6-chloro-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine-1,1-dioxide
3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
3-Dichloromethyl-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide
3-Dichloromethylhydrochlorothiazide
6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
6-Chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide1,1-dioxide
6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide
6-Chloro-3-(dichloromethyl)3,4-dihydro-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide
6-Chloro-3-[dichloromethyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
6-Chloro-3-dichloromethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-Dioxide
6-Chloro-3-dichloromethyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine1,1-dioxide
AB00052117
AC1L1KMB
AC1Q6TQ0
AR-1H7280
Achletin
American Urologicals Brand of Trichloromethiazide
Anistadin
Aponorin
Aquazide
BPBio1_000825
BRD-A28940325-001-05-9
BRN 0629145
BSPBio_000749
BSPBio_002926
C07767
CHEMBL1054
CID5560
Carvacron
Chlopolidine
Ciba 7057-Su
Cretonin
D00658
D014237
DB01021
Diu-Hydrin
Diurazida
Diurese
Diuroral
DivK1c_000366
EINECS 205-118-8
Esmarin
Eurinol
Fluitran
Flurese
Flurese (VAN)
Flutra
Gangesol
HMS1570F11
HMS1921G13
HMS2090G08
HMS2092O19
HMS501C08
HSDB 3406
Hydrotrichlorothiazide
IDI1_000366
Intromene
Isestran
Jones Brand of Trichloromethiazide
KBio1_000366
 
KBio2_001000
KBio2_003568
KBio2_006136
KBio3_002146
KBioGR_000833
KBioSS_001000
Kubacron
LS-40435
MLS000028705
MLS001076545
Metahydrin
Metatensin
MolPort-003-666-298
NCGC00089756-02
NCGC00089756-03
NCIOpen2_007750
NINDS_000366
NSC 61560
NSC61560
Nakva
Naqua
Naqua (TN)
Naquasone
Prestwick0_000825
Prestwick1_000825
Prestwick2_000825
Prestwick3_000825
Prestwick_1020
SMR000058712
SPBio_000916
SPBio_002670
SPECTRUM1500590
ST51015129
Salurin (wadel)
Schebitran
Schering Brand of Trichlormethiazide
Spectrum2_000948
Spectrum3_001373
Spectrum4_000367
Spectrum5_001074
Spectrum_000520
T1016_SIGMA
T1318
Tachionin
Tolcasone
Trichlordiuride
Trichlorex
Trichlormas
Trichlormetazid
Trichlormethiazid
Trichlormethiazide (JP15/USP/INN)
Trichlormethiazide W/ Reserpine
Trichlormethiazide [INN:JAN]
Trichlormethiazidum
Trichlormethiazidum [INN-Latin]
Trichloromethiadiazide
Trichloromethiazide
Triclordiuride
Triclormetiazida
Triclormetiazida [INN-Spanish]
Triclormetiazide
Triclormetiazide [DCIT]
Triclormetiazide [Italian]
Triflumen
UNII-Q58C92TUN0
WLN: T66 BSWM EM DHJ DYGG HG ISZW
trichlormethiazide
trichloromethiazide, 6
39
GlimepiridePhase 4, Phase 322293479-97-13476
Synonyms:
1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea
1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea
3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro
4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
64598P
93479-97-1
AB00513874
AC-476
AC1L1G0T
Amarel
Amaryl
Amaryl (TN)
Amaryl, Glista OD, Glimepiride
Avaglim
BPBio1_000751
BRD-K34776109-001-03-4
BRD-K42693031-001-01-8
BRN 5365754
BSPBio_000681
Bio-0049
C07669
C24H34N4O5S
CAS-93479-97-1
CCRIS 7083
CHEBI:5383
CHEMBL1481
CID3476
CPD000466368
D00593
DB00222
Endial
G2295_SIGMA
Glimepirid
Glimepirida
Glimepirida [Spanish]
Glimepiride (JAN/USP/INN)
Glimepiride [USAN:BAN:INN]
Glimepiridum
Glimepiridum [Latin]
 
Glimepride
Glimer
Glimépiride
Glymepirid
HMS1570C03
HMS2052L03
HMS2090K18
HOE 490
Hoe-490
I06-0029
I06-2285
LS-136752
MLS000759495
MLS001076674
MLS001401419
MolPort-003-847-587
MolPort-003-987-461
MolPort-005-941-721
NCGC00016960-01
NCGC00161404-01
NCGC00161404-02
NCGC00181757-01
Novo-glimepiride
Oprea1_382896
PMS-glimepiride
Prestwick0_000651
Prestwick1_000651
Prestwick2_000651
Prestwick3_000651
Ratio-glimepiride
Roname
S1344_Selleck
SAM001246710
SMR000466368
SPBio_002602
Sandoz glimepiride
Solosa
TL8005924
UNII-6KY687524K
ZINC00537791
glimepiride
40
NorepinephrinePhase 4, Phase 3, Phase 2, Phase 166451-41-2439260
Synonyms:
(-)-(R)-Norepinephrine
(-)-Arterenol
(-)-Arterenol free base
(-)-NORADRENALINE
(-)-Noradrenaline
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
AC1L96ZT
ALBB-006229
Adrenor
Aktamin
Arterenol
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-Dihydroxyphenylethanolamine
L-3,4-dihydroxyphenylethanolamine
L-Arterenol
L-Noradrenaline
L-Norepinephrine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-noradrenaline
LS-42676
LT03330026
 
LT4
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Nor-adrenaline
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
Noradrenaline
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
PDSP1_001111
PDSP2_001095
SGCUT00123
SPBio_001048
SPECTRUM1500436
STK503776
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
Spectrum_001009
Sympathin E
UNII-X4W3ENH1CV
bmse000404
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
noradrenaline
norepinefrina
norepinephrine
norepinephrinum
to_000024
41
LiraglutidePhase 4293204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
42
CarteololPhase 4, Phase 3, Phase 1551781-06-72583
Synonyms:
5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one
5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one
5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
51781-06-7
51781-21-6 (mono hydrochloride)
AB00514682
AC1L1E05
BPBio1_000542
BRD-A42167015-003-03-7
BSPBio_000492
C06874
C16H24N2O3
CARTEOLOL
CHEBI:3437
CHEMBL839
CID2583
Carteolol
 
Carteolol (INN)
Carteolol HCl
Carteolol Monohydrochloride
Carteolol [INN:BAN]
Carteololum
Carteololum [INN-Latin]
D07624
DB00521
I14-8021
L000777
LS-142779
NCGC00179541-01
Oprea1_672850
Prestwick0_000446
Prestwick1_000446
Prestwick2_000446
Prestwick3_000446
SPBio_002431
UNII-8NF31401XG
43
SpiraprilPhase 4283647-97-65311447
Synonyms:
(2S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,9-dithia-3-azaspiro[4.4]nonane-2-carboxylic acid
83647-97-6
AC1NSKNL
BRN 4277924
C22H30N2O5S2
CHEBI:101967
CHEMBL431
CID5311447
D08529
DB01348
 
Espirapril [Spanish]
LS-63095
Not established
Renormax
Sandopril
Sch-33844
Setrilan
Spirapril
Spirapril (INN)
Spirapril [INN:BAN]
Spiraprilum [Latin]
TI-211-950
44
FurosemidePhase 4, Phase 3, Phase 218354-31-93440
Synonyms:
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
41733-55-5 (mono-hydrochloride salt)
5-18-09-00555 (Beilstein Handbook Reference)
54-31-9
AB00052001
AC-11067
AC1L1FXW
AC1Q557O
AKOS000266625
ARONIS24304
Acetic acid potassium salt
Aisemide
Aldalix
Aldic
Aluzine
Anfuramaide
Apo-Frusemide
Apo-Furosemide
Aquarid
Aquasin
Arasemide
BIDD:GT0139
BPBio1_000443
BRD-K78010432-001-05-8
BRN 0840915
BSPBio_000401
BSPBio_002054
Beronald
Bio-0044
Bioretic
Bristab
Bristurin
C12H11ClN2O5S
CAS-54-31-9
CCRIS 1951
CHEBI:47426
CHEMBL35
CID3440
CPD000058202
Cetasix
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]
D00331
D005665
DB00695
DB07799
Depix
Desal
Desdemin
Di-Ademil
Dihydroflumethiazide
Dirine
Disal
Discoid
Disemide
Diucardin
Diumide-K
Diural
Diurapid
Diuretic Salt
Diuretic salt
Diurin
Diurolasa
Diusemide
Diusil
Diuzol
DivK1c_000575
Dranex
Dryptal
Durafurid
EINECS 200-203-6
Edemid
Edenol
Eliur
Elodrine
Endural
Errolon
Eutensin
F0182
F4381_SIGMA
FUN
FUROSEMIDE USP
Farsix
Finuret
Fluidrol
Fluss
Franyl
Frumex
Frumide
Frumil
Frusedan
Frusema
Frusemid
Frusemide
Frusemin
Frusenex
Frusetic
Frusid
Fu sid
Fulsix
Fuluvamide
Fuluvamine
Furanthril
Furanthryl
Furantral
Furantril
Furanturil
Furesis
Furetic
Furex
Furfan
Furix
Furmid
Furo-Basan
Furo-Puren
Furo-puren
Furobeta
Furocot
Furodiurol
Furodrix
Furomen
Furomex
Furomide M.D
Furomide M.D.
Furorese
Furosan
Furose
Furosedon
Furosemid
Furosemida
Furosemida [INN-Spanish]
Furosemide
Furosemide "mita"
Furosemide (JP15/USP/INN)
Furosemide Monohydrochloride
Furosemide Monosodium Salt
Furosemide [USAN:INN:JAN]
Furosemidu
Furosemidu [Polish]
Furosemidum
Furosemidum [INN-Latin]
Furosemix
Furoside
Furosifar
Furosix
Furoter
Furovite
Fursemid
Fursemida
Fursemide
Fursol
Fusid
Fusidic acid
 
Golan
HMS1569E03
HMS1920B03
HMS2090K06
HMS2091H05
HMS501M17
HSDB 3086
Hissuflux
Hoe-058A
Hydol
Hydrenox
Hydrex
Hydro
Hydro-Rapid
Hydro-rapid
Hydroled
I04-0179
IDI1_000575
Impugan
Jenafusid
KBio1_000575
KBio2_001580
KBio2_004148
KBio2_006716
KBio3_001274
KBioGR_001259
KBioSS_001580
Katlex
Kofuzon
Kolkin
Kutrix
LB 502
LB-502
LS-204
Lasemid
Lasex
Lasiletten
Lasilix
Lasix
Lasix (TN)
Lasix (tn)
Lasix Retard
Lasix Special
Lasix, Frusemide, Furosemide
Laxur
Lazix
Leodrine
Less Diur
Liside
Logirene
Lowpston
Lowpstron
Luscek
MLS001066374
MLS001306403
Macasirool
Marsemide
Metflorylthiazidine
Methforylthiazidine
Mirfat
Mita
Moilarorin
MolPort-001-641-065
Myrosemide
NCGC00016241-01
NCGC00090893-01
NCGC00090893-02
NCGC00090893-03
NCGC00090893-05
NCGC00090893-06
NCI-C55936
NINDS_000575
NSC 269420
NSC269420
Nadis
Nelsix
Neo-Renal
Neo-renal
Nephron
Nicorol
Novosemide
Octan Draselny
Octan draselny
Odemase
Odemex
Oedemex
Olmagran
Oprea1_667724
Osyrol
Polysquall A
Prefemin
Prestwick0_000341
Prestwick1_000341
Prestwick2_000341
Prestwick3_000341
Prestwick_752
Profemin
Promedes
Promide
Protargen
Puresis
Radisemide
Radonna
Radouna
Retep
Rodiuran
Rontyl
Rosemide
Rosis
Rusyde
S1603_Selleck
SAM002264614
SMP1_000129
SMR000058202
SPBio_001129
SPBio_002322
SPECTRUM1500310
STK177334
Sal Diureticum
Sal diureticum
Salinex
Salix
Salix (brand of furosemide)
Salurex
Salurid
Saluron
Seguril
Selectofur
Sigasalur
Sisuril
Spectrum2_001005
Spectrum3_000437
Spectrum4_000560
Spectrum5_000744
Spectrum_001100
Spirofur
Synephron
TL8003563
Transit
Trofurit
UNII-7LXU5N7ZO5
UPCMLD-DP022
UPCMLD-DP022:001
Uremide
Uresix
Urex
Urex-M
Urian
Uridon
Uritol
Urosemide
Vergonil
Vesix
WLN: T5OJ B1MR CG FVQ DSZW
Yidoli
Zafimida
fulvamide
furosemide
furosemide ''mita''
less Diur
45glucagonPhase 4441
46
SerotoninPhase 4, Phase 3, Phase 2, Phase 1351050-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
47
PioglitazonePhase 4, Phase 3, Phase 2428111025-46-84829
Synonyms:
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione
(+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
105355-27-9
111025-46-8
198077-89-3
2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione
5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione
5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione
5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
AB1004597
AC-1021
AC1L1J1Q
AD 4833
AD-4833
Actos
Actos (TN)
Actost
BRD-A48430263-003-02-4
BSPBio_002723
C07675
C19H20N2O3S
CHEBI:8228
CHEMBL595
CID4829
D08378
DB01132
Duetact
Glustin
HMS2089H14
HS-0047
 
HSDB 7322
I06-0089
KBio2_002103
KBio2_004671
KBio2_007239
KBio3_001943
KBioGR_001619
KBioSS_002103
LS-151327
MolPort-002-508-211
NCGC00163128-01
NCGC00163128-02
Pioglitazona
Pioglitazona [INN-Spanish]
Pioglitazone
Pioglitazone HCl
Pioglitazone Hydrochloride
Pioglitazone [BAN:INN]
Pioglitazone [Ban:Inn]
Pioglitazone [INN:BAN]
Pioglitazonum
Pioglitazonum [INN-Latin]
SPBio_001897
Spectrum2_001679
Spectrum3_001002
Spectrum4_001130
Spectrum5_001480
Spectrum5_002067
Spectrum_001623
U 72107
U 72107A
U-72107
U72,107A
UNII-X4OV71U42S
Zactos
nchembio790-comp10
pioglitazone (INN)
pioglitazone HCl
48
CilnidipinePhase 4, Phase 3, Phase 2, Phase 18132203-70-45282138
Synonyms:
(+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester
132203-70-4
2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
AC-270
AC1NQZJB
Atelec
Atelec (TN)
BRD-A07875874-001-01-6
Bio-0164
C1493_SIGMA
C27H28N2O7
CHEBI:31399
CHEBI:438069
CHEMBL452076
CID5282138
 
Cilnidipine (JAN/INN)
Cilnidipine [INN]
Cinaldipine
Cinalong
D01173
FRC 8653
FRC-8653
HMS2089J07
I06-0491
LS-131293
MolPort-003-845-950
NCGC00162150-01
NCGC00162150-02
NCGC00162150-03
S1293_Selleck
STK623341
Siscard
cilnidipine
49Rosuvastatin CalciumPhase 4, Phase 3, Phase 2, Phase 1440147098-20-2
50
paroxetinePhase 422361869-08-743815
Synonyms:
(-)-(3S,4R)-4-(P-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine
(-)-Paroxetine
(-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine
(-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine
(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
(3S-trans)-3-((1,3-Benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine
110429-35-1
3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride
61869-08-7
63952-24-9
64006-44-6 (maleate)
78246-49-8 (hydrochloride)
AB00514724
AC1L2AKL
AC1Q1H18
AC1Q4LV6
Aropax
BIDD:GT0673
BPBio1_000949
BRD-K37991163-003-02-7
BRL 29060
BRL-29060
BSPBio_000861
C07415
C19H20FNO3
CHEBI:7936
CHEMBL490
CID43815
Casbol
D02362
DB00715
DivK1c_006884
FG 7051
FG-7051
FT-0085087
Frosinor
 
HMS2090H05
I14-7752
KBio1_001828
KBio2_002232
KBio2_004800
KBio2_007368
KBioSS_002232
LS-114249
MolPort-003-849-791
Motivan
NCGC00025355-02
NCGC00025355-03
NCGC00025355-04
NCGC00025355-05
NCGC00025355-06
NCGC00025355-07
NCGC00025355-08
NNC-20-7051
Paroxetina
Paroxetina [INN-Spanish]
Paroxetine
Paroxetine (TN)
Paroxetine (USP/INN)
Paroxetine Hcl
Paroxetine [USAN:INN:BAN]
Paroxetinum
Paroxetinum [INN-Latin]
PaxPar
Paxetil
Paxil
Paxil CR
Pexeva
Prestwick3_000851
Seroxat
Seroxat CR
SpecPlus_000788
Spectrum5_001665
Spectrum_001752
TL8003967
UNII-41VRH5220H
[3H]Paroxetine
paroxetine

Interventional clinical trials:

(show top 50)    (show all 5035)
idNameStatusNCT IDPhase
1IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION StudyCompletedNCT00416611Phase 4
2Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.CompletedNCT00171561Phase 4
3Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant HypertensionCompletedNCT02426099Phase 4
4Morning Hypertension and Preminent Therapy StudyCompletedNCT00795847Phase 4
5A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential HypertensionCompletedNCT01251146Phase 4
6Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients With Sleep Apnea and no Daytime SleepinessCompletedNCT00127348Phase 4
7Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger PhysiologyCompletedNCT00317486Phase 4
8Safely Change From Bosentan to Ambrisentan in Pulmonary HypertensionCompletedNCT01330108Phase 4
9Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401CompletedNCT01105117Phase 4
10Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled HypertensionCompletedNCT00267176Phase 4
11A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)CompletedNCT01431508Phase 4
12An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and MoreCompletedNCT01979913Phase 4
13Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) SubjectsCompletedNCT00741819Phase 4
14Treatment of Pediatric Hypertension With Altace TrialCompletedNCT00044265Phase 4
15Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)CompletedNCT00303459Phase 4
16Effect of Acute Arterial Hypertension on Morphine's Requirements and Postsurgical Pain.CompletedNCT01897155Phase 4
17Clonidine Versus Captopril for Treatment of Postpartum Very High Blood PressureCompletedNCT01761916Phase 4
18Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of HypertensionCompletedNCT01202175Phase 4
19Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current MonotherapyCompletedNCT00351130Phase 4
20Epoprostenol for Injection in Pulmonary Arterial HypertensionCompletedNCT01105091Phase 4
21Nebivolol in Patients With Systolic Stage 2 HypertensionCompletedNCT01057251Phase 4
22Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)CompletedNCT00617305Phase 4
23An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With HypertensionCompletedNCT00412932Phase 4
24Exercise Training in Type 2 Diabetes and HypertensionCompletedNCT00212303Phase 4
25A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II HypertensionCompletedNCT00430638Phase 4
26Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With HypertensionCompletedNCT00277472Phase 4
27Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate HypertensionCompletedNCT00861016Phase 4
28Hypertension and Cardiovascular Risk FactorsCompletedNCT00171782Phase 4
29Treatment of Adiposity Related hypErTension (TARGET)CompletedNCT01138423Phase 4
30Amiloride for Resistant HypertensionCompletedNCT02122731Phase 4
31Comparative Study of Valsartan and Amlodipine Versus Amlodipine Alone in HypertensionCompletedNCT00333489Phase 4
32Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular DysfunctionCompletedNCT02133352Phase 4
33Nitrate and Hypertension in Heart Transplanted PatientsCompletedNCT00449059Phase 4
34Study of Sildenafil Effects in Combination With Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Associated Pulmonary HypertensionCompletedNCT01055405Phase 4
35Doxazosin and Ramipril in HypertensionCompletedNCT02901977Phase 4
36Evaluation of Periop Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preop HypertensionCompletedNCT02441842Phase 4
37Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk HypertensionCompletedNCT00139555Phase 4
38Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.CompletedNCT00334386Phase 4
39Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)CompletedNCT00882947Phase 4
40Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular HypertensionCompletedNCT00061503Phase 4
41Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 DiabetesCompletedNCT00738023Phase 4
42Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)CompletedNCT01462565Phase 4
43STITCH (Simplified Therapeutic Intervention To Control Hypertension)CompletedNCT00129909Phase 4
44Renal Response to Lower Body Negative Pressure in Pre-hypertensive StatesCompletedNCT01734096Phase 4
45Russian Study of the Efficacy and Safety of Tarka in Patients With HypertensionCompletedNCT00235001Phase 4
46CPAP in SAHS Patients With HypertensionCompletedNCT02398032Phase 4
47Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed DoseCompletedNCT00034840Phase 4
48Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)CompletedNCT01464424Phase 4
49PHARES Study: Management of Resistant HypertensionCompletedNCT00224549Phase 4
50STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia)CompletedNCT00637078Phase 4

Search NIH Clinical Center for Hypertension, Essential

Inferred drug relations via UMLS66/NDF-RT44:


Cochrane evidence based reviews: hypertension, essential

Genetic Tests for Hypertension, Essential

About this section

Genetic tests related to Hypertension, Essential:

id Genetic test Affiliating Genes
1 Essential Hypertension25
2 Hypertension25
3 Susceptibility to Salt-Sensitive Essential Hypertension23

Anatomical Context for Hypertension, Essential

About this section

MalaCards organs/tissues related to Hypertension, Essential:

34
Heart, Kidney, Endothelial, Lung, Testes, Liver, Eye

Animal Models for Hypertension, Essential or affiliated genes

About this section

MGI Mouse Phenotypes related to Hypertension, Essential:

39
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537510.3ACE, AGT, AGTR1, CYP11B2, INS, NOS2
2MP:000536710.2ACE, AGT, AGTR1, CYP11B2, INS, NOS2
3MP:000363110.1ADD1, AGT, AGTR1, CYP11B2, ECE1, GNB3
4MP:00053859.8ACE, AGT, AGTR1, CYP11B2, ECE1, INS

Publications for Hypertension, Essential

About this section

Articles related to Hypertension, Essential:

idTitleAuthorsYear
1
Comparison of the twenty-four-hour blood pressure profile in elderly subjects with isolated systolic hypertension, essential hypertension and normotension. (1818900)
1991

Variations for Hypertension, Essential

About this section

Clinvar genetic disease variations for Hypertension, Essential:

5
id Gene Variation Type Significance SNP ID Assembly Location
1PTGISPTGIS, IVS9, T-C, +2single nucleotide variantPathogenic

Copy number variations for Hypertension, Essential from CNVD:

6 (show all 17)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1714271269818942132349534Copy numberHypertension
2109399172580000031800000GainHypertension
3112710174093040778774742Copy numberHypertension
41371342138750000144750000DeletionARHGAP15Hypertension
51371382138750000144750000DeletionGTDC1Hypertension
61371422138750000144750000DeletionHNMTHypertension
71371462138750000144750000DeletionKYNUHypertension
81371502138750000144750000DeletionLOC64702Hypertension
91371542138750000144750000DeletionLRP1BHypertension
101371582138750000144750000DeletionNXPH2Hypertension
111371622138750000144750000DeletionSPOPLHypertension
121393372179004449242951149Copy numberHypertension
131953555150157836180857866Copy numberHypertension
141953755150183562180857866Copy numberHypertension
15210789631416574170899992Copy numberHypertension
16211339632582950170899992Copy numberHypertension
17211385632609209170899992Copy numberHypertension

Expression for genes affiliated with Hypertension, Essential

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Hypertension, Essential patients vs. healthy controls: 33
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1LINC01420long intergenic non-protein coding RNA 1420Blood+3.270.005

Search GEO for disease gene expression data for Hypertension, Essential.

Pathways for genes affiliated with Hypertension, Essential

About this section

GO Terms for genes affiliated with Hypertension, Essential

About this section

Biological processes related to Hypertension, Essential according to GeneCards Suite gene sharing:

(show all 26)
idNameGO IDScoreTop Affiliating Genes
1regulation of renal output by angiotensinGO:000201911.0ACE, AGT
2hormone catabolic processGO:004244711.0ACE, ECE1
3regulation of systemic arterial blood pressure by endothelinGO:000310011.0ECE1, NOS3
4regulation of systemic arterial blood pressure by renin-angiotensinGO:000308111.0ACE, AGTR1
5regulation of blood vessel size by renin-angiotensinGO:000203411.0AGT, AGTR1
6positive regulation of guanylate cyclase activityGO:003128411.0NOS2, NOS3
7positive regulation of cholesterol esterificationGO:001087311.0AGT, AGTR1
8renin-angiotensin regulation of aldosterone productionGO:000201810.9AGT, AGTR1, REN
9regulation of vasodilationGO:004231210.9ACE, AGTR1, ECE1
10beta-amyloid metabolic processGO:005043510.8ACE, REN
11low-density lipoprotein particle remodelingGO:003437410.8AGT, AGTR1
12positive regulation of cardiac muscle hypertrophyGO:001061310.8AGT, ECE1
13regulation of renal sodium excretionGO:003581310.8AGT, AGTR1
14positive regulation of NAD(P)H oxidase activityGO:003386410.8AGT, AGTR1
15positive regulation of macrophage derived foam cell differentiationGO:001074410.7AGT, AGTR1
16positive regulation of cellular protein metabolic processGO:003227010.7AGT, AGTR1, INS
17positive regulation of vasodilationGO:004590910.7AGT, INS, NOS2, NOS3
18angiotensin maturationGO:000200310.7ACE, AGT, REN
19nitric oxide biosynthetic processGO:000680910.6NOS2, NOS3
20arginine catabolic processGO:000652710.6NOS2, NOS3
21nitric oxide mediated signal transductionGO:000726310.5AGT, NOS2, NOS3
22kidney developmentGO:000182210.4ACE, AGT, AGTR1, REN
23regulation of blood volume by renin-angiotensinGO:000201610.4AGT, REN
24blood vessel remodelingGO:000197410.3ACE, AGT, NOS3
25regulation of blood pressureGO:000821710.3ACE, ACSM3, AGT, GNB3, NOS3, REN
26regulation of vasoconstrictionGO:001922910.1ACE, AGT, AGTR1, ECE1

Molecular functions related to Hypertension, Essential according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1bradykinin receptor bindingGO:003171111.0ACE, AGTR1
2nitric-oxide synthase activityGO:000451711.0NOS2, NOS3
3arginine bindingGO:003461811.0NOS2, NOS3
4tetrahydrobiopterin bindingGO:003461711.0NOS2, NOS3
5insulin-like growth factor receptor bindingGO:000515910.9INS, REN
6endopeptidase activityGO:000417510.9ACE, ECE1, REN
7FMN bindingGO:001018110.4NOS2, NOS3
8heme bindingGO:002003710.2CYP11B2, CYP3A5, NOS2, NOS3, PTGIS
9iron ion bindingGO:000550610.0CYP11B2, CYP3A5, NOS3, PTGIS

Sources for Hypertension, Essential

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet